Cargando…

EGFR-specific T cell frequencies correlate with EGFR expression in head and neck squamous cell carcinoma

BACKGROUND: In head and neck squamous cell carcinoma (HNSCC), expression levels of the epidermal growth factor receptor (EGFR) correlate with poor prognosis and decreased survival rates. As the mechanisms responsible for cellular immune response to EGFR in vivo remain unclear, the frequency and func...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schuler, Patrick J, Boeckers, Petra, Engers, Rainer, Boelke, Edwin, Bas, Murat, Greve, Jens, Dumitru, Claudia A, Lehnerdt, Goetz F, Ferris, Robert L, Andrade Filho, Pedro A, Brandau, Sven, Lang, Stephan, Whiteside, Theresa L, Hoffmann, Thomas K
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198929/ https://www.ncbi.nlm.nih.gov/pubmed/21970318 http://dx.doi.org/10.1186/1479-5876-9-168

Ejemplares similares

In vitro chemosensitivity of head and neck cancer cell lines
por: Schuler, PJ, et al.
Publicado: (2010)

EGFR-Specific Tyrosine Kinase Inhibitor Modifies NK Cell-Mediated Antitumoral Activity against Ovarian Cancer Cells
por: Mallmann-Gottschalk, Nina, et al.
Publicado: (2019)

Anti-Epidermal Growth Factor Receptor (EGFR) Antibodies Overcome Resistance of Ovarian Cancer Cells to Targeted Therapy and Natural Cytotoxicity
por: Gottschalk, Nina, et al.
Publicado: (2012)

Dendritic cell generation and CD4(+)CD25(HIGH)FOXP3(+ )regulatory T cells in human head and neck carcinoma during Radio-chemotherapy
por: Schuler, PJ, et al.
Publicado: (2011)

The EGFR-STYK1-FGF1 axis sustains functional drug tolerance to EGFR inhibitors in EGFR-mutant non-small cell lung cancer
por: Eggermont, Carolien, et al.
Publicado: (2022)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

Targeting the tyrosine kinase inhibitor-resistant mutant EGFR pathway in lung cancer without targeting EGFR?
por: De Greve, Jacques, et al.
Publicado: (2020)

The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells
por: Greve, Gabriele, et al.
Publicado: (2015)

Reversing EGFR Mediated Immunoescape by Targeted Monoclonal Antibody Therapy
por: Concha-Benavente, Fernando, et al.
Publicado: (2017)

EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC
por: Liu, Yan, et al.
Publicado: (2019)

Targeting USP13‐mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non‐small cell lung cancer
por: Giron, Philippe, et al.
Publicado: (2021)

TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR(+) head and neck cancer cells
por: Ming Lim, Chwee, et al.
Publicado: (2013)

Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas
por: Bergmann, Christoph, et al.
Publicado: (2011)

Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
por: Chen, Gang, et al.
Publicado: (2010)

EGFR Suppression Inhibits the Sphere Formation of MCF7 Cells Overexpressing EGFR
por: Novak, D. D., et al.
Publicado: (2023)

Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Della Corte, Carminia Maria, et al.
Publicado: (2017)

Radiotherapy in brain metastases from EGFR-mutated non-small cell lung cancer
por: Bhandari, Shruti, et al.
Publicado: (2021)

egfr overexpression in squamous cell carcinoma of the penis
por: Lavens, N., et al.
Publicado: (2010)

A Bispecific Inhibitor of the EGFR/ADAM17 Axis Decreases Cell Proliferation and Migration of EGFR-Dependent Cancer Cells
por: Soto-Gamez, Abel, et al.
Publicado: (2020)

Pharmacogenomics of EGFR-targeted therapies in non–small cell lung cancer: EGFR and beyond
por: Delaney, Christopher, et al.
Publicado: (2015)

EGFR amplification induces sensitivity to antiEGFR therapy in pancreatic acinar cell carcinoma
por: Richard, Corentin, et al.
Publicado: (2018)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

EGFR/Met association regulates EGFR TKI resistance in breast cancer
por: Mueller, Kelly L, et al.
Publicado: (2010)

BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level
por: Kim, Ji Hye, et al.
Publicado: (2021)

Correction: Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR
por: Corte, Carminia Maria Della, et al.
Publicado: (2022)

Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip
por: Li, Ren, et al.
Publicado: (2017)

Plasma membrane domain organization regulates EGFR signaling in tumor cells
por: Lajoie, Patrick, et al.
Publicado: (2007)

EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
por: Antonicelli, Alberto, et al.
Publicado: (2013)

EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma
por: Ravanpay, Ali C., et al.
Publicado: (2019)

Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR(WT), EGFR(T790M), and EGFR(L858R))
por: Abo Al-Hamd, Mahmoud G., et al.
Publicado: (2023)

Critical roles for EGFR and EGFR–HER2 clusters in EGF binding of SW620 human carcinoma cells
por: Wollman, Adam J. M., et al.
Publicado: (2022)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Predicting EGFR Mutation in Lung Adenocarcinoma: Development and Validation of the EGFR Mutation Predictive Score (EMPS) in Bali, Indonesia
por: Njoto, Edwin Nugroho, et al.
Publicado: (2023)

Brk/PTK6 Sustains Activated EGFR Signaling through Inhibiting EGFR Degradation and Transactivating EGFR
por: Li, X, et al.
Publicado: (2012)

Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth
por: Yao, Nan, et al.
Publicado: (2020)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
por: Cheng, Wen-Chien, et al.
Publicado: (2021)

Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK
por: Dittmann, Klaus, et al.
Publicado: (2008)

Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
por: Britain, Colleen M., et al.
Publicado: (2018)

Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
por: Kuiper, J L, et al.
Publicado: (2016)

Selective toxicity of TGF-alpha-PE40 to EGFR-positive cell lines: selective protection of low EGFR-expressing cell lines by EGF.
por: Kirk, J., et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_oilsn8nj2hp458kkqaa24uaqop